Pancreatic Cancer: Planning Ahead for Metastatic Spread

Ingunn M Stromnes1, Philip D Greenberg2

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Cancer Cell
|June 15, 2016
PubMed

Insights

Pancreatic cancer metastasis relies on CXCR2 and neutrophils. Combining CXCR2 and PD1 inhibition in mice with advanced disease significantly improved survival, unlike individual treatments.

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterized by metastasis and therapy resistance.
  • Understanding the mechanisms driving PDAC progression is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of CXCR2 and neutrophils in pancreatic cancer metastasis.
  • To evaluate the therapeutic potential of inhibiting CXCR2 and PD1 in advanced PDAC.

Main Methods:

  • Utilized mouse models of advanced pancreatic ductal adenocarcinoma.
  • Assessed the impact of CXCR2 and PD1 inhibition on metastasis and survival.
  • Examined the cooperative and individual effects of these targeted therapies.

Main Results:

  • CXCR2 expression and neutrophils were identified as critical drivers of pancreatic cancer metastasis.
  • Inhibition of both CXCR2 and PD1 synergistically prolonged survival in mice with advanced disease.
  • Individual inhibition of CXCR2 or PD1 did not significantly improve survival outcomes.

Conclusions:

  • CXCR2 and neutrophils are essential for pancreatic cancer metastasis.
  • Combined CXCR2 and PD1 blockade represents a promising therapeutic strategy for advanced pancreatic ductal adenocarcinoma.